IPRP

IPRP predicts survival in acute myeloid leukemia (AML) patients using an immunity- and pyroptosis-related gene-pair signature to refine prognostic classification.

Key Features:

• Gene-pair signature: The signature comprises 15 genes assembled via a gene pairing methodology to generate relative expression-based pairs.
• Batch-effect mitigation: The gene pairing approach reduces batch effects across diverse transcriptomic datasets and sequencing technologies.
• Validation across cohorts: Performance was validated on five independent AML cohorts totaling 1,327 patients.
• Comparative performance: The IPRP score demonstrated superior survival prediction relative to ten existing signatures.
• Added prognostic value: The score provides prognostic information beyond age and ELN2017 risk classification.
• Nomogram: Implemented as a 4-factor nomogram for risk scoring.
• Pan-cancer applicability: Pan-cancer analyses indicate potential relevance for prognostic prediction and tumor-immune interaction analysis across multiple solid tumors.

Scientific Applications:

• AML risk stratification: Stratifies AML patients by predicted survival risk using immunity- and pyroptosis-related gene-pair information.
• Tumor immunity and cell death research: Supports studies on the interplay between immune response and pyroptosis in cancer biology.
• Pan-cancer prognostic analysis: Enables exploration of prognostic markers and tumor-immune interactions across diverse solid tumor types.

Methodology:

Integration and analysis of gene expression data for pyroptosis- and immune-related genes; construction of a 15-gene-pair signature using a gene pairing strategy to harmonize data and mitigate batch effects; retrospective multi-cohort validation across five AML cohorts (1,327 patients) with comparisons to ten existing signatures.